Response to TMS treatment for depression associated with higher levels of psychological well-being.


Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
06 2022
Historique:
received: 02 09 2021
revised: 09 03 2022
accepted: 21 03 2022
pubmed: 5 4 2022
medline: 18 5 2022
entrez: 4 4 2022
Statut: ppublish

Résumé

Treatment resistant depression (TRD) is a complex condition associated with a great deal of disability and suffering. The relationship between TRD and psychological well-being (PWB) appears to be more complex than a simple antithesis. Transcranial magnetic stimulation (TMS) is a well-tolerated treatment for TRD. However successful, a drawback for TMS is that it has a lack of predictive biomarkers for treatment response. Our study focuses on the relationship between PWB and treatment resistant depression, and how PWB relates to TMS treatment response. We hypothesized that TMS treatment responders would have higher levels of PWB at baseline. In this study of 21 patients with TRD, we used the Ryff Scales of Psychological Well-Being and Patient Health Questionnaire-9 (PHQ-9). We found a significant relationship between environmental mastery, purpose in life, self-acceptance, and total PWB with baseline depression but no significant correlation between autonomy, personal growth, and positive relations with others and baseline PHQ-9 scores. No Ryff domain of PWB significantly predicted change in PHQ-9 score. Interestingly, however, we found that TMS responders had higher levels of autonomy (M(SD) = 62.10(10.46), p = 0.022) and personal growth (M(SD) = 65.00(11.04), p = 0.007) than non-responders at baseline. These specific aspects of well-being appear to be distinct from depression and particularly important in treatment response. This discovery suggests that assessing PWB might prove clinically useful when assessing future candidates for TMS treatment of TRD. Further research is necessary to evaluate the effects of TMS on PWB since these may be distinct from its effect on depression symptomology.

Identifiants

pubmed: 35378486
pii: S0022-3956(22)00159-5
doi: 10.1016/j.jpsychires.2022.03.030
pmc: PMC9673128
mid: NIHMS1835525
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

142-146

Subventions

Organisme : NIMH NIH HHS
ID : K23 MH125145
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM108540
Pays : United States
Organisme : NIMH NIH HHS
ID : T32 MH019113
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Références

Psychol Med. 2020 Jan;50(2):264-272
pubmed: 30674359
Depress Anxiety. 2012 Jul;29(7):587-96
pubmed: 22689344
Psychiatr Serv. 2020 Apr 1;71(4):312-318
pubmed: 31847739
Behav Res Ther. 2017 Apr;91:58-63
pubmed: 28160719
J Adult Dev. 2010 Jun;17(2):110-119
pubmed: 20502508
Brain Stimul. 2016 May-Jun;9(3):336-346
pubmed: 27090022
Psychol Res Behav Manag. 2019 Aug 30;12:767-792
pubmed: 31507332
Am J Psychiatry. 2004 Oct;161(10):1872-6
pubmed: 15465985
J Affect Disord. 2020 Apr 15;267:264-282
pubmed: 32217227
Clin Psychopharmacol Neurosci. 2019 Feb 28;17(1):25-33
pubmed: 30690937
J Consult Clin Psychol. 2005 Jun;73(3):539-48
pubmed: 15982151
Psychother Psychosom. 2003 Sep-Oct;72(5):268-75
pubmed: 12920331
Biol Mood Anxiety Disord. 2012 Aug 17;2:14
pubmed: 22901565
Lancet. 2018 Nov 24;392(10161):2299-2312
pubmed: 30396512
J Psychiatr Pract. 2016 May;22(3):193-202
pubmed: 27123799
BMC Public Health. 2013 Feb 08;13:119
pubmed: 23390882
Pers Individ Dif. 2021 Feb 1;169:
pubmed: 34421163
Health Psychol Open. 2015 Jul-Dec;2(2):
pubmed: 26617988
Psychol Med. 1998 Mar;28(2):475-80
pubmed: 9572104
J Affect Disord. 2010 May;122(3):213-7
pubmed: 19706357
Am J Public Health. 2010 Dec;100(12):2366-71
pubmed: 20966364
Lancet. 2015 Feb 14;385(9968):640-648
pubmed: 25468152
Depress Anxiety. 2016 Aug;33(8):746-53
pubmed: 27059158
JAMA Psychiatry. 2021 Mar 1;78(3):337-339
pubmed: 33237320
J Psychiatry Neurosci. 2004 Jul;29(4):268-79
pubmed: 15309043
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942

Auteurs

Catherine Toth (C)

University of Iowa, Department of Psychological and Brain Sciences, G60 Psychological and Brain Sciences Building, 340 Iowa Avenue, Iowa City, IA, 52246, USA. Electronic address: ctoth1@uiowa.edu.

Marcie L King Johnson (ML)

University of Iowa, Department of Psychological and Brain Sciences, G60 Psychological and Brain Sciences Building, 340 Iowa Avenue, Iowa City, IA, 52246, USA.

Amanda Heinzerling (A)

University of Iowa Hospitals and Clinics, Department of Psychiatry, 200 Hawkins Drive, T223 General Hospital, Iowa City, IA, 52242, USA.

Nicholas Trapp (N)

University of Iowa Hospitals and Clinics, Department of Psychiatry, 200 Hawkins Drive, T223 General Hospital, Iowa City, IA, 52242, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH